Dietary fats in the gastrointestinal lumen

Dietary fats in the gastrointestinal lumen consist primarily of triglycerides, phospholipids, and cholesterol esters ingested through the diet. These lipids must undergo a complex process of emulsification by bile salts and enzymatic hydrolysis by gastric and pancreatic lipases to be converted into smaller, absorbable molecules like free fatty acids and monoglycerides [NIH: NBK535404]. While dietary fats themselves are not therapeutic targets in the classical sense of being a receptor or enzyme, they are the substrates upon which several weight-loss and lipid-lowering drugs act. For example, the drug Orlistat binds to and inhibits gastric and pancreatic lipases within the lumen, preventing the breakdown of approximately 30% of ingested fat, which is then excreted in the feces [StatPearls: NBK542202]. This mechanism is utilized to treat obesity and manage caloric intake by reducing the net absorption of energy-dense lipids. Other pharmacological agents may interfere with the emulsification of these fats or their transport across the intestinal epithelium. However, the presence of undigested fats in the colon can lead to clinical symptoms such as steatorrhea and urgent bowel movements. Furthermore, chronic inhibition of fat absorption can interfere with the uptake of essential fat-soluble vitamins, necessitating clinical monitoring [PubMed: 10848511].

Other names

Dietary lipidsIntestinal triglyceridesExogenous fatsGastrointestinal triglycerides

Inhibition of gastrointestinal lipases (e.g., Orlistat) prevents the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides [StatPearls: NBK542202]. Bile acid sequestrants (e.g., Colesevelam) bind bile acids, interfering with the emulsification and subsequent absorption of dietary fats [StatPearls: NBK548315].